Galapagos | GLPG - Selling And Administration Expenses


Galapagos reported EUR44.42M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
argenx SE USD 429.62M 93.32M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.47B 193M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025